
In response to Drug Enforcement Administration proposals to limit telehealth prescriptions for buprenorphine and other controlled substances after the COVID-19 public health emergency to a 30-day supply unless the prescriber or referring clinician have evaluated the patient in person, AHA today urged the agency to establish a special registration process (as statutorily mandated) to waive the in-person evaluations for practitioners who register with the DEA.